According to the business intelligence report titled ‘Global Influenza Vaccines Market 2021 – 2027’, available with MarketStudyReport, global influenza vaccines market is estimated to expand significantly between 2021-2027.
 

Growing geriatric populace, increasing disease awareness, and launch of quadrivalent influenza vaccines are the key factors driving global influenza vaccines market expansion.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/3676278/
 

Rising government support & surveillance regarding vaccination, investments by leading companies, and increasing federal funding will aid revenue inflow as well.
 

Due to the COVID-19 pandemic, immunization camps & programs organized by healthcare organizations have been affected adversely. However, vaccination rates have risen significantly due to free vaccination offered to citizens by governments and other healthcare operatives.
 

On the other hand, delay in development of vaccines due to varying regulatory requirements across countries, high initial investment, and time consuming nature of vaccine development process will act as challenges for businesses operating in this domain.
 

In the report, historical records and the latest trends are compared to provide industry partakers with an extensive understanding of the workings of this business sphere. The study uses these statistics to forecast the market growth rate over the forecast period 2021-2027.
 

From regional frame of reference, North America held majority of global influenza vaccines market share in the recent past owing to increasing incidence of influenza, launch of new vaccines, and rising technological developments in vaccine administration. Meanwhile, Middle East & Africa market is slated to witness significant growth between 2021-2027, due to enhancement in healthcare facilities, rising disposable incomes, and growing number of awareness programs.
 

Leading players formulating the competitive landscape of worldwide influenza vaccines market are Sanofi Pasteur (Sanofi S.A.), Seqirus (CSL Limited), GlaxoSmithKline plc, AstraZeneca plc, BioDiem Ltd., Mylan N.V., Novavax Inc., Moderna Inc., Altimmune Inc., Medicago Inc., Pneumagen Limited, Daiichi-Sankyo Co. Ltd., FluGen Inc., EpiVax Inc., Imutex Limited, Gamma Vaccines Pty Ltd., Versatope Therapeutics Inc., Hualan Biological Engineering Inc., BiondVax Pharmaceuticals Ltd., and Shanghai Institute of Biological Products Co., Ltd.